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Introduction and Aim. Nitric oxide (NO) can trigger cardiac differentiation of embryonic stem cells (ESCs), indicating a cardiogenic
function of the NO synthetizing enzyme(s) (NOS). However, the involvement of the NO/NOS downstream effectors soluble
guanylyl cyclase (sGC) and cGMP activated protein kinase I (PKG-I) is less defined. Therefore, we assess the involvement of
the entire NO/NOS/sGC/PKG-I pathway during cardiac differentiation process.Methods. Mouse ESCs were differentiated toward
cardiac lineages by hanging drop methodology for 21 days. NOS/sGC/PKG-I pathway was studied quantifying genes, proteins,
enzymatic activities, and effects of inhibition during differentiation. Percentages of beating embryoid bodies (mEBs) were evaluated
as an index of cardiogenesis. Results and Discussion. Genes and protein expression of enzymes were increased during differentiation
with distinctive kinetics and proteins possessed their enzymatic functions. Exogenous administered NO accelerated whereas the
blockade of PKG-I strongly slowed cardiogenesis. sGC inhibition was effective only at early stages and NOS blockade ineffective.
Of NOS/sGC/PKG-I pathway, PKG-I seems to play the prominent role in cardiac maturation. Conclusion. We concluded that
exogenous administered NO and other pharmacological strategies able to increase the activity of PKG-I provide new tools to
investigate and promote differentiation of cardiogenic precursors.
1. Introduction and Aim of the Study
Nitric oxide (NO), a biological active free radical, is an intra-
cellular and intercellularmessenger inmammalian cells [1, 2],
where its signaling cascade plays an important modulatory
role in many physiological and pathological conditions [1, 3].
Besides its well-recognized function in endothelium-derived
smooth muscle relaxation [4], synaptic transmission, and
immunological responses [5], NO is also a key regulator
of heart function via modulation of excitation-contraction
coupling [6, 7] and myocardial growth [8].
NO is produced by three different enzymes (namely,
neuronal, inducible, and endothelial nitric oxide synthase,
nNOS, iNOS, and eNOS) and acts directly or indirectly
through the stimulation of the soluble guanylate cyclase
(sGC), a heterodimeric enzyme, and the subsequent forma-
tion of cyclic GMP (cGMP). Among other direct effects,
cGMP activates protein kinase G type I (PKG-I), a ser-
ine/threonine kinase exerting many regulatory functions in
the heart [9]. On myocardial tissue low activation level of
NO/NOS/sGC/PKG-I signaling increases contractility, while
high levels exert a negative inotropic effect [7]. In this setting
many functional proteins are substrates for PKG-I, including
L-type calcium channels and phospholamban (PLB), which
in the phosphorylated form relieves its inhibitory effect on
sarcoendoplasmic Ca-ATPasi type 2 (SERCA2), enhancing
calcium uptake into the sarcoendoplasmic reticulum (SR)
and reducing cytosolic free calcium [10, 11].
Increasing evidences point to the participation of reactive
oxygen species (ROS), such as NO, hydroxyl radical (OH−),
Hindawi Publishing Corporation
Stem Cells International
Volume 2016, Article ID 2868323, 10 pages
http://dx.doi.org/10.1155/2016/2868323
2 Stem Cells International
hydrogen peroxide (H
2
O
2
), and superoxide anion (O
2
−) as
important triggers for cardiac differentiation of embryonic
stem cells (ESCs) [12, 13]. In stem and progenitor cells, phys-
iological levels of intracellular ROS are required to maintain
genomic stability and to increase the proliferation/migration
capabilities [14, 15]. Moreover, Cecchi and coauthors [16]
demonstrated that ROS as well as NO could be involved
in cardiomyogenesis. Additionally, treatment of mouse ESCs
(mESCs) with ascorbic acid upregulates NADPH oxidase
isoforms, which in turn phosphorylates eNOS and increases
cGMP formation leading to enhancing cardiac differentiation
from undifferentiated precursors. Interestingly, many stud-
ies have shown that NO/NOS/sGC/PKG-I pathway exerts
cardioprotective effects in ischemia-reperfusion injury [17],
providing the basis to hypothesize that NO/NOS/cGC/PKG-
I pathway might be involved in cardiac differentiation of
resident stem cell.
In EZ1 mESCs, eNOS (mNos3), and sGC (mGuCy) genes
are expressed at early stage of cardiac differentiation [18].
Moreover, treatments of mESCs and human ESCs with NO-
donors and sGC activators alone or in combination increase
mRNA expression of cardiac specific transcription factor
Nkx2.5 and of myosin light chain 2, suggesting a possible
cardiogenic role of NO/sGC/PKG-I pathway in undiffer-
entiated precursors [19]. More recently, the NO-donor S-
nitrosocysteine proved to enhance cardiac differentiation and
spontaneous contraction of D3mESC [20], corroborating the
hypothesis of a cardiogenic function ofNO/sGCpathway and
that of the downstream effector PKG-I.
To test this hypothesis we used CGR8 mESCs induced
to differentiate toward the cardiac lineage and assessed the
involvement of the entire signaling pathway NO/NOS/sGC/
PKG-I during the differentiation process. Our data provide
evidence to support the hypothesis that exogenous admin-
istered NO-donors have the potential to promote cardiac
differentiation of cardiogenic precursors.
These data have been partially presented as an abstract at
the Congress of the European Society of Cardiology, Council
on Basic Cardiovascular Science, held in Florence on 8–10
July 2016 [21].
2. Material and Methods
2.1. Culture of Mouse Embryonic Stem Cells. Mouse embry-
onic stem cells (mESCs) of the line CGR8were used [22]. Cell
were propagated at 37∘C and 5%CO
2
in gelatin coated dishes,
using Glasgow Minimum Essential Medium BHK-21 (G-
MEM BHK-21), supplemented with 10% fetal bovine serum
(FBS) (GIBCO Invitrogen, Milan, Italy), 2mM glutamine,
0.1mM 2-mercaptoethanol, 1mM sodium pyruvate, 1%
nonessential amino acids, 1% penicillin/streptomycin (Sigma
Aldrich, Milan, Italy), and 1000 units/mL of Leukaemia
Inhibiting Factor (LIF, 10 𝜇g/mL; Millipore, Milan, Italy). All
other products for cell cultures were purchased from GIBCO
Invitrogen. Prior to splitting, cultures were treated with
trypsin/EDTA (Sigma Aldrich) at room temperature for 30–
60 sec in order to eliminate differentiated cells. These culture
conditions allowed CGR8 mESCs to maintain an undiffer-
entiated phenotype characterized by round-growing, tightly
packed, refrangent colonies.
2.2. Differentiation of CGR8 ESCs into Embryoid Bodies
in Control Condition. CGR8 mESCs were differentiated
using the hanging drop method [23]. Drops of differen-
tiating medium containing 600 cells were seeded on the
lid of bacteriological dishes. When the dish was closed,
this allowed cells to aggregate and grow in suspension
(for 2 days) and eventually form mouse embryoid bod-
ies (mEBs). Differentiation medium, in control condition,
consisted of medium G-MEM BHK21 supplemented with
10% FBS, 2mM glutamine, 0.1mM 2-mercaptoethanol, 1mM
sodium pyruvate, 1% nonessential amino acids, and 1%
penicillin/streptomycin. Thereafter, mEBs were resuspended
in differentiation medium and grown in suspension in bacte-
riological dishes for 4 days. On the 6th day, mEBs were plated
on gelatin coated dishes, where they attached. After 24–36 h
from plating, cardiac differentiation was recognizable from
the occurrence of spontaneous contracting areas. mEBs were
monitored daily by inverted microscopy; the beating mEBs
were counted from day 7 to day 21 (D7–D21). mEBs matu-
ration was followed for no longer than 21 days according to
experimental protocols.
2.3. Drugs Administration of NO-Donors or NO Pathway
Inhibitors during Differentiation of CGR8 ESCs into Embryoid
Bodies. In parallel experiments, CGR8mESCs were differen-
tiated in control conditions and in the presence of the NO-
donor or inhibitors of the NO-sGC-PKG-I pathway. Drugs
were administered from day 0 (hanging drop formation) to
the end of experiments, renewing media every 2 days:
1,4:3,6-Dianhydro-D-glucitol 5-nitrate (isosorbide
mononitrate, ISN, 50𝜇M, Sigma Aldrich) is a
member of the antianginal drug class clinically used
to treat Angina Pectoris Prophylaxis, esophageal
spasm, and heart failure as a NO-donor.
1H-[1,2,4]Oxadiazolo[4,3-a]quinoxalin-1-one (ODQ,
1 𝜇M, SigmaAldrich) is a highly selective, irreversible,
heme-site inhibitor of soluble guanylyl cyclase (sGC).
NG-Methyl-L-arginine (L-NMA, 100 𝜇M - Sigma
Aldrich) is one of themost commonly used inhibitors
of the nitric oxide synthase (NOS).
KT 5823 (1 𝜇M, Sigma Aldrich) is selective inhibitor
of PKG-I.
2.4. Molecular Expression of Stemness andCardiac Specific and
NOS-sGC-PKG-I Pathway Genes
Isolation of Total RNA, Reverse Transcription (RT), and Real-
Time PCR (Q-PCR). Samples ofmEBs were collected at differ-
ent time-points of differentiation formolecular assessment by
RNA extraction, reverse transcription, and gene expression
analysis using quantitative real-time PCR (Q-PCR).
Total RNA was isolated from mEBs using NucleoSpin
RNA kit (Macherey-Nagel, Du¨ren, Germany). Subsequently,
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complementary DNA (cDNA) was synthesized from 1𝜇g
total RNA using iScript cDNA Synthesis kit (Bio-Rad,
Milan, Italy). All of these steps were performed according to
the manufacturer’s instructions.
Real-time quantitative PCR (Q-PCR) was performed
using the default thermocycler program for all genes: 1
minute of preincubation at 95∘C followed by 40 cycles for
15 seconds at 95∘C, 1 minute at 60∘C and 15 seconds at
95∘C, 1 minute at 60∘C, and 1 minute 95∘C. Individual
real-time PCR reactions were carried out in 10 𝜇L vol-
umes in a 96-well plate (Applied Biosystems, London,
UK) containing 2𝜇L RNAse-free water, 1 𝜇L of sense and
antisense primers (Bio-Rad), and 5𝜇L iTaq SYBR Green
Universal Supermix (Bio-Rad) plus 2 𝜇L of cDNA sample
(5 ng/𝜇L). Each experiment was repeated in triplicate, and
quantitative PCR analysis was performed in triplicate and
analyzed with Delta Ct-method. Mouse Glyceraldehyde-3-
Phosphate Dehydrogenase (mGapdh) was used for internal
normalization. Results were analyzed by assuming as 100%
the maximal value of gene expression in each experiment.
The amplicon context sequences of the primers were listed
in Table 1S (see Supplementary Material available online at
http://dx.doi.org/10.1155/2016/2868323).
2.5. Expression of NOS3, sGC, and PKG-I Proteins during
mEBs Maturation. Protein levels were analyzed by western
blotting analysis. At different maturation days, mEBs were
collected with 100 𝜇L of cold Phosphate-Buffered Saline
(PBS) and homogenized in lysis buffer containing 50mM
Tris-HCl pH 8.0, 150mM NaCl, 1mM EDTA, 0.5% Triton
X-100, and complete protease inhibitor (Roche Diagnostics,
Milan, Italy). The homogenate was incubated on ice for 20
minutes. Then, the suspension was sonicated on ice with a
wave sonicator for 45minutes. After centrifugation (12000×g
for 10 minutes at 4∘C), aliquots containing 100 𝜇g (8% of
acrylamide forNOS3) or 50𝜇g total proteins (10% acrylamide
for sGC and PKG-I) were blotted on SDS-page. Proteins were
revealed using rabbit policlonal anti-NOS3 (eNOS; 1 : 1000;
Santa Cruz Biotechnology, Dallas, TX, USA), mouse mon-
oclonal anti-sGC-𝛽1 (1 : 1000, Santa Cruz Biotechnology),
and rabbit polyclonal anti-PKG-I (1 : 1000, Cells Signalling,
Danvers, MA, USA) primary antisera and the corresponding
secondary antibodies. Densitometric analysis was performed
with the “ImageJ” software and results were normalized
to GAPDH immunoreactivity (1 : 1000 rabbit antiserum,
Cells Signalling) as internal control. Total protein quan-
tification was performed using bicinchoninic acid assay
(BCAmethod). Bicinchoninic acid and CuSO
4
solution were
purchased from Sigma Aldrich.
2.6. NOS and sCG Activity. Cyclic GMP cell content was
evaluated as marker of NOS and sGC activity. At day 14
mEBs were washed with warm Dulbecco’s Modified Eagle’s
Medium (DMEM) and incubated with 100 𝜇M 3-isobutyl-
1-methylxanthine (IBMX), a nonspecific inhibitor of cAMP
and cGMP phosphodiesterases (IBMX-DMEM) for 15min at
37∘C.Then, mEBs were treated according to Table 1 in a total
volume of 10mL.
Table 1: mEBs incubation time and drug administration.
Groups 15min 30min
CTR IBMX-DMEM IBMX-DMEM
100𝜇M L-NMA L-NMA IBMX-DMEM
100𝜇M SNAP IBMX-DMEM SNAP
50𝜇M ISN IBMX-DMEM ISN
1 𝜇MODQ + 100 𝜇M SNAP ODQ SNAP
1 𝜇MODQ + 100 𝜇M ISN ODQ ISN
Table 2: mEBs incubation time and drug administration.
Groups 15min 10min
CTR IBMX-DMEM IBMX-DMEM
1 𝜇MKT5823 KT5823 IBMX-DMEM
1 𝜇M cGMPS IBMX-DMEM cGMPS
1 𝜇MKT5823 + 1 𝜇M cGMPS KT5823 cGMPS
100𝜇M SNAP IBMX-DMEM SNAP
50𝜇M ISN IBMX-DMEM ISN
All drugs were dissolved in IBMX-DMEM and incuba-
tion was performed at 37∘C. At the end of treatments, mEBs
were rapidly frozen andmaintained at−20∘Cuntil use. cGMP
(pg/mg of total proteins) was measured by ELISA kit (Enzo
Life Science, Exeter UK). Briefly, mEBs were recovered in
200𝜇L ice-water and sonicated on ice with a wave sonicator
for 30min and then centrifuged (12000×g for 10 minutes at
4∘C). Twenty 𝜇L of samples was used for protein determi-
nation (BCA method). Each sample was acidified (200 𝜇L of
HCl 0.1M, after 15min at room temperature), hard vortexed,
and then centrifuged (12000×g for 10 minutes at 4∘C). cGMP
quantity was measured using ELISA kit according to manu-
facturer’s protocol and absorbancewas read in aWallacVictor
spectrophotometer (Perkin Elmer, Milan, Italy). IBMX and
S-nitroso-N-acetyl-DL-penicillamine (SNAP, S-nitrosothiol
which serves as a NO-donor) were purchased from Sigma
Aldrich.
2.7. PKG-I Activity. To evaluate PKG-I activity, serine/
threonine phosphorylated proteins (containing −1 or +1
phenylalanine/tryptophan residues) were measured. Briefly,
at day 14mEBs were washed with DMEM and incubated with
IBMX-DMEM for 15min at 37∘C. Then, mEBs were treated
according to Table 2 in a total volume of 10mL.
All drugs were dissolved in IBMX-DMEM and incuba-
tion was performed at 37∘C and thenmEBs were then rapidly
frozen in liquid nitrogen and maintained at −20∘C until use.
Aliquots of cell proteins (20𝜇g) were blotted on 10% acry-
lamide gels and serine/threonine phosphorylated proteins
revealed using rabbit anti-phospho-serine/threonine (1 : 1000
rabbit antiserum, Abcam, Cambridge, UK). Densitometric
analysis was performed using the “ImageJ” software and
results were normalized to GAPDH immunoreactivity as
internal control. Unstimulated sample density (GAPDH nor-
malized) was set as 100% in each experiment. Aliquots of
same cell proteins (50 𝜇g) were blotted on 10% acrylamide
gels and PKG-I was analyzed as already described. The
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Figure 1: Time-course of gene expression. (a) Relative expression of mNos3, mGuCy1𝛽, and mPrkg1 genes. (b) Relative expression of mOct4
(pluripotency marker), mGata4, and mNkx2.5 (cardiac specific) genes. Data are the mean ± s.e. of 3 different differentiations; measures were
performed in triplicate.
membrane-permeant, stable activator of PKG-I Sp-8-pCPT-
PET-cGMPS (cGMPS) was obtained from BIOLOG, Life
Science Institute (Bremen, Germany).
2.8. Dosage LDH in Conditioned Medium of mESCs. Cells
release LDH after tissue damage. Since LDH is a fairly stable
enzyme, it has been widely used to evaluate cell damage
and toxicity. The mEBs were maintained from day 0 in
the presence of 100 𝜇M L-NMA, 1 𝜇M ODQ, 1 𝜇M KT5823,
or control conditions and supernatants were collected and
frozen at various days of differentiation until use.The amount
of the enzyme LDH in mEBs supernatant was evaluated by
Lactate Dehydrogenase Activity Assay Kit (Sigma Aldrich)
following the manufacturer’s directions. NADH was specif-
ically detected by colorimetric assay (450 nm) using Wallac
Victor spectrophotometer.
2.9. Data Analysis and Statistics. All data are expressed as
the mean ± standard error of the mean (s.e.m.). Offline
data analysis was performed by using Origin 9.1 (MicroCal
Software Inc., MA, USA). Statistical analysis was performed
by using ANOVA, followed by Bonferroni’s post hoc test.
A probability value of less than 0.05 was considered as
significant.
3. Results
3.1. mNos3, mGuCy1b, and mPrkg1 in mESCs and during
Cardiac Differentiation. Gene expression analysis of mNos3,
mGuCy1b, and mPrkg1 was performed in undifferentiated
mESCs and during cardiac differentiation. Data show that
mNos3, mGuCy1b, and mPrkg1 were expressed at very low
levels in undifferentiated cells, but they collectively increased
during cardiac differentiation, albeit with different time-
courses. mNos3 (Figure 1(a)) showed a bell-shaped curve,
with a robust raise at day 5 and a peak at day 8, a key develop-
mental period in in vitro cardiogenic process. mGuCy1b and
mPkg1 increased robustly at day 5, reached the maximum at
day 8, and maintained these expressions until the end of the
maturation process (day 21).
In the same preparations, we monitored cardiac dif-
ferentiation of mESCs, analyzing gene expression profile
of pluripotency (mOct4 and mNanog), early mesoder-
mic (mBrachyury) and mature cardiac marker (mNkx2.5,
mMef2c and mGata4) genes. Following the process, the
pluripotency transcription factor mOct4 was clearly down-
regulated, as expected, showing a specular time-course
compared to mPrkg1, mGuCy1b, and mNos3 in the first
phase (Figure 1(b)). Similarly to mOct4, mNanog expression
steadily dropped (Figure 1S) during the differentiation; con-
versely, cardiac transcription factors mNkx2.5 (Figure 1(b)),
mGata4 (Figure 1(b)), and mMef2c (Figure 1S) were progres-
sively upregulated from day 0 to day 8 and then declined,
following a bell-shaped curve that is almost superimposable
to that of mNos3. The mesodermal marker mBrachyury
showed a transient expression pattern peaking at day 2
(Figure 1S).
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Figure 2: NOS3, sGC-𝛽1, and PKG-I protein expression in mESCs, in differentiating mEBs and in adult mouse hearts. Protein expression of
NOS3 (a), sGC-𝛽1 (b), and PKG-I (c) inmESCs andmEBs at days 5, 8, 10, and 16 of differentiation and in the adultmouse heart. Representative
images of gels are shown. (d) It shows time-courses of all proteins. Data are the mean ± s.e. of at least 3 differentiations.
3.2. NOS3, sCG, and PKG-I Protein Expression. At different
stages of cardiac differentiation, NOS3, sCG, and PKG-I
protein levels were evaluated by western blot analysis. Results
are shown in Figures 2(a), 2(b), and 2(c). All enzymes were
undetectable in mESCs; NOS3 and PKG-I proteins appeared
at day 5 of differentiation, while sGC expression was detected
later. NOS3 maximal level was observed at day 8 and then
declined, being well detectable at day 10 and essentially
absent at day 16 (Figure 2(a)). sGC-1𝛽 was evident at day
10 and rapidly increased until day 16 (Figure 2(b)), showing
similar values at day 12. Finally, PKG-I showed a slower,
progressive increase during the differentiation process that
reached a plateau level at day 10 and remained constant until
day 16 (Figure 2(c)). Figure 2(d) shows the superimposition
of protein time-courses during the entire differentiation
process.
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Figure 3: Soluble GC and NOS enzymatic activity. Soluble GC and
NOS enzymatic activity evaluated by cGMP measure in mEBs at
day 14 of differentiation in control condition and in the presence of
100𝜇M L-NMA, 100𝜇M SNAP, 50 𝜇M ISN, 1 𝜇M ODQ + 100𝜇M
SNAP, and 1 𝜇MODQ + 50 𝜇M ISN. All measures were carried out
in the presence of 100𝜇M IBMX. ∗𝑃 < 0.05 and ∗∗𝑃 < 0.01 versus
CTR; §𝑃 < 0.05 versus SNAP, one-way ANOVA followed by post hoc
Bonferroni’s test. For method, see Table 1. Data are the mean ± s.e.
of at least 3 differentiations; measures were performed in duplicate.
3.3. Soluble GC and NOS Enzymatic Activities. To assess sGC
and NOS enzymatic activities, we estimated cGMP produc-
tion in different experimental conditions at day 14, a time-
point when both proteins are clearly expressed (Figure 3).
After 60min incubation with IBMX, in control condition
cGMP concentration was 0.84 ± 0.187 pmol/mg of total
proteins. After incubation with L-NMA, an inhibitor of
NOS, cGMP quantity was slightly decreased to about 60%,
suggesting that in control condition NOS basal activity is
able to induce a modest, albeit detectable, sGC stimulation.
SNAP or ISN, two NO-donors, significantly increased cGMP
levels more than 3 times (3.80 and 3.25, resp.) compared
to control. When either SNAP or ISN was added in the
presence of the sGC inhibitor ODQ, increase of cGMP was
significantly (SNAP) or strongly (ISN) prevented, giving
values not different from control.
3.4. PKG-I Enzymatic Activity. PKG-I activity was evaluated
by western blot analysis of phosphorylated proteins. Figures
4(a) and 4(b) show representative panels of phosphorylated
proteins obtained in different experimental conditions, which
were analyzed by semiquantitative analysis (Figure 4(c)).
Both NO-donors (SNAP and ISN) significantly increased
protein phosphorylation compared to control; similarly, the
cGMP membrane permeable cGMPS significantly increased
protein phosphorylation by 250% (Figure 4(d)). The PKG-
I inhibitor KT 5823 did not modify significantly protein
phosphorylation compared to basal conditions, while it
significantly prevented by 50% the phosphorylation induced
by cGMPS (Figure 4(d)).
PGK-I protein expression levels detected in each exper-
imental sample used to quantify phosphorylation were very
similar (Figure 2S), ruling out the possibility that differences
in phosphorylation could be dependent on PKG-I expression
variability.
3.5. Functional Assessment of the Effect of NO-Donor or
NOS, sGC, and PKG-I Inhibition on Spontaneous Beating
of Differentiating Embryoid Bodies. To assess the impact of
NO/NOS/sGC/PKG-I pathway on a functional marker of
cardiac differentiation,we evaluated the percentage of beating
embryoid bodies in different experimental conditions. As
expected, in control condition beating increased fromday 8 of
differentiation, reaching a maximal value at day 12 (Figure 5,
insert).
In parallel experiments, we assessed the effect exerted
by the NO-donor ISN, the NOS-inhibitor L-NMA, the sGC
inhibitor ODQ, or the PKG I-inhibitor KT5823, setting con-
trol values of each day as 100% (Figure 5). In the presence of
ISN, percentage of beating increased significantly compared
to control evaluated at day 8 (𝑃 < 0.001 versus control and
other treatments), while it was slightly higher at day 9 (𝑃 <
0.05 versus other treatments) and at day 10 (𝑃 < 0.05 versus
control and other treatments). Thereafter, values became
undistinguishable from control. ODQ reducedmEBs beating
at days 8 and 9 (𝑃 < 0.05); then the difference disappeared.
KT5823 strongly reduced beating at day 8 (𝑃 < 0.001) and
maintained this inhibitory effect constant. Inhibition of NOS
did not significantly reduce beating at any stage ofmaturation
(Figure 5).
3.6. Lactate Hydrogenase Activity. Since the reduction of the
contractile activity observed in the presence of NO-sGC-
PKG-I inhibitors could mirror a latent toxicity of the selected
drugs, we performed the dosage of LDH as a marker of a
specific cell toxicity. LDH activity was 3.01 ± 0.604mU/mL
in control conditions at day 4. This value remained similar,
independently of the maturation day. LDH activity was
increased in the supernatant of mEBs treated with ODQ
at day 4, but then it returned to control value, indicating
a relative toxicity caused by ODQ at the beginning of the
treatment, which however disappeared shortly thereafter. All
the other treatments did not significantly influence LDH
activity. Results are depicted in Figure 3S.
4. Discussion
Assessment of cardiac differentiation in vitro is a prerequisite
to identify factors and drugs able to increase the cardiogenic
potential of stem cells not only during organogenesis, but
also during the healing and reparation after degenerative
processes of the heart. In particular, after cardiac ischemic
insults, the self-reparative program is limited, thus requiring
additional studies to identify new effective therapies and/or
novel mechanistic insights into the action of drugs able to
potentiate the healing process. Among others, NO-donors
are a treatment of choice for ischemic and postischemic
insult. In the heart, endogenous and exogenous NO acts
through activation of sGC that produces cGMP, which in
turn increases the phosphorylation activity of PKG-I, a
final effector enzyme responsible for complex regulatory
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Figure 4: PKG-I activity; it was evaluated by serine/threonine phosphorylated proteins in mEBS at day 14 of differentiation in control
condition and in presence of 100𝜇M SNAP, 50 𝜇M ISN, 1 𝜇M KT5823, 1 𝜇M KT5823 + 1 𝜇M cGMPS, and 1 𝜇M cGMPS. All measures were
carried out in the presence of 100𝜇M IBMX. Representative images of gels are shown in (a) and (b). ∗𝑃 < 0.05 versus control, one-way
ANOVA followed by post hoc Bonferroni’s test. For method, see Table 2. Data are the mean ± s.e. of at least 3 different differentiations.
function of cardiac contractility [7]. Whether the function of
NO/NOS/cGMP/PKG-I pathway also extends to the cardio-
genic process of stem cells is only partially known.Therefore,
in our study we investigated thoroughly the involvement of
the pathway in the cardiac differentiation ofmESCs, directing
our efforts to the physiological and pharmacological role
of NO (endogenously produced by NOS3 or exogenously
administered as ISN) and of the main downstream effectors
sGC and PKG-I.
During the cardiogenic process of CGR8 ESC, our data
showed that expression of mNos3, mGuCy1b, and mPkrg1
parallels the increase of cardiac specific gene pattern and
the decrease of pluripotent genes (Oct4 and Nonog). In
particular, mNos3 gene maximal expression was observed
at day 8, when cardiac specific genes reach their maximal
expression (Figure 1(b)). Thereafter, gene expression levels
declined and remained stable throughout the process. Inter-
estingly, our data on eNOS time-course of expression in
differentiating CGR8 mESCs are in line with that detected
in mESCs on ascorbic acid treatment [24]. At variance with
eNOS, mGuCy andmPkrg1 expression appeared delayed and
remained stably high throughout the developmental period.
These data confirm the results already reported for the cardiac
differentiation of a different cell line, the EZ1mouse ESC [18],
where a similar temporal pattern of Nos3/sGuCy expression
was detected.Of note, our investigation extends the transcript
analysis to mPkrg1, the downstream enzyme of the pathway,
responsible for amount of phosphorylation of target proteins.
More importantly, our study provides evidence that the entire
protein panel comprised in the NO pathway (NOS3-sGC-
PKG-I) is functionally expressed in the cardiogenic system; it
exhibits a developmental time-course that closely resembles
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Figure 5: Percentage of beating mEBs during cardiac differenti-
ation. The percentage of beating mEBs was calculated at differ-
ent time-points of mEBs cardiac differentiation. Cells were incu-
bated with 50 𝜇M ISN (NO-donor) or NOS/sGC/PKG-I pathway
inhibitors (resp., 100𝜇M L-NMA, 1 𝜇M ODQ, or 1 𝜇M KT5823)
from day 0 to day 16. Insert: beating mEBs (percentage of the total
bodies) in control condition. One-way ANOVA followed by post
hoc Bonferroni’s test. ∗∗∗𝑃 < 0.001, ∗∗𝑃 < 0.01, and ∗𝑃 < 0.05
versus control; §§𝑃 < 0.01 versus control and all other treatments;
∧
𝑃 < 0.05 versus all other treatments. Data are the mean ± s.e. of at
least 4 different differentiations.
that of the relative primary transcripts, thus suggesting a
complete translationmachinery in the differentiating system.
Indeed, NOS3 protein was readily detectable at the beginning
of the differentiation, while its expression decreases in the
late developmental phase. sGC was maximally expressed at
day 16 of differentiation, later than the respective gene, even
if small quantities of the protein were already detectable at
day 10. PKG-I was clearly detectable starting from day 5; it
increased soon after day 8 and maintained this level until the
end of the differentiation process. Functionally, all enzymes
possess their typical activities, as determined by measuring
directly or indirectly their metabolic or functional products
at day 14. Accordingly, cGMP quantities were enhanced by
stimulating sGC with NO-donors and reduced by blocking
NOS activity. Moreover, PKG-I mediated phosphorylation
capacity was increased by NO-donors and cGMP stable
analog, showing a full functionalmaturation of the enzymatic
system attained during cardiac differentiation. A similar
time-course of NOS3-sGC-PKG-I protein expression has
been reported for EZ1 mouse ESCs [18], where sGC activity
and its enhancement by NO-donors were measured at day
14. At variance with our study, sGC in EZ1 mouse ESCs was
detectable from day 5 to day 7, a discrepancy likely dependent
on the specific cell line.
One of the indices of cardiac lineage specification is
the development of spontaneous beating areas in mEB, a
requisite that in CGR8 ESCs typically appear 7-8 days after
differentiation onset and then peak around day 12. We
observed that administration of exogenous NO or endoge-
nous cGMP/PKG-I pathway blockade is able to change the
number and timing of beating areas in opposite directions.
Of note, the increased beating observed after exogenous
NO treatment at the beginning of the differentiation (day
8, Figure 5) suggests that the stimulation of NO pathway
may promote cardiac differentiation of ESCs.This hypothesis
is corroborated by similar findings observed by Hodge and
coauthors [20] in a different line of genetically modified
mESCs, where exposure to S-nitrosocysteine, an exoge-
nous NO-donor, increased the number of contracting areas
detected at early phase of differentiation (10th day). In the
same setting, inhibition of endogenous NO production via
NOS blockade was ineffective in reducing the percentage
of contracting areas [20]. Accordingly, a different study
reported thatNOS inhibition in basal conditionwas unable to
influence the spontaneous beating percentage of mEBs [24].
Our data extend the above results providing evidence thatNO
downstream effectors sGC and PKG-I are also importantly
involved in the cardiogenic process. Indeed, in the presence
of ODQ or KT 5823, sGC, and PKG-I inhibitors, respectively,
appearance of the contractile phenotype was substantially
delayed (Figure 5), leading to concluding that the entire
signaling pathway is necessary to complete the cardiogenic
process. Interestingly, sGC inhibition was able to reduce the
percentage of beating mEBs only at the beginning of the
differentiation (i.e., until day 10), when, though sGC protein
expression is low, its functional activity is sufficient to allow
beating appearance, as revealed by ODQ effect. Since sGC
inhibition was effective to delay beating appearance, whereas
blockade of endogenous NO production did not produce
any evident effect, we hypothesize that other endogenous
activators of sGC, such as carbon monoxide (CO), might be
involved in the differentiation process. CO is an endogenous
activator of sGC with a 50 time lower efficacy than NO [25],
produced by heme oxygenase 1 and heme oxygenase 2. Our
preliminary data show that heme oxygenase 1 and 2 genes
are expressed in parallel with NO pathway enzymes during
cardiac differentiation of CGR8 ESCs, thus corroborating the
idea that CO may represent a potential candidate for sGC
activation in this setting. Considering that heme oxygenase
1 upregulation plays a protective role in cardiac stem cell
apoptosis [26], we can hypothesize that in our experimental
condition CO could reinforce or substitute NO in sGC
stimulation, a key enzyme in cardiac maturation. Further
research is necessary to clarify the role of CO and heme
oxygenase in ESC biology and cardiac differentiation.
Our data demonstrate that PKG-I blockade strongly
delays the development of spontaneous beating areas
throughout the whole differentiation process at variance
with the limited effect of sGMP inhibition, a finding that
suggests a predominant role of PKG-I over sGMP during
the cardiogenic process. This leading function of PKG-I
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on cardiogenic differentiation agrees with the notion that a
basal activity is also present at very low cGMP levels, which
are only sufficient to provide a minimal enzymatic activity
[27]. Furthermore, a central role of the PKG-I activity in
the cardiogenic process is also demonstrated by tadalafil
treatment, a cGMP-specific phosphodiesterase 5A (PDE5A)
inhibitor, which proved to promote survival and proliferation
of mesenchymal stem cells in a rat model of infarction [28].
Even if obtained in a different model, these data indicate an
important role of the PKG-I activity shared by different stem
precursors, to enhance the cardiogenic potential.
Our findings demonstrate that blockade of NOS-cGMP-
PKG-I pathway in developing mEBs is not associated with
release of LDH in the supernatant; this suggests that the
blockade of a specific program and not an unspecific toxicity
is likely the mechanism that suppresses cardiac differentia-
tion.
In our study we did not assess the molecular mechanism
linking PKG-I activity to cardiogenic process. This issue
needs further studies besides the aims of present investiga-
tions; however some interesting clues may be drawn consid-
ering the role of PKG-I in intracellular Ca2+ homeostasis.
At early differentiation stages, spontaneous contractions of
differentiating ESCs are dependent on spontaneous cytosolic
free Ca2+ oscillations. These latter mainly depend on SR
discharge and subsequent reuptake. Indeed,mRNAs/proteins
that characterize the mature functional SR in adult cardiac
myocytes (type 2 ryanodine receptor, junctophilin-2, calse-
questrin, PLB, and SERCA2a) are already expressed at early
stages of differentiating ESCs and well before the appear-
ance of spontaneous contractions [29]. Additionally, in the
same setting functional inositol-1,4,5-trisphosphate receptor
(IP3R) channels proved to contribute to Ca2+ rhythmic
discharge from SR [30], meaning that a complex network of
Ca2+ regulating proteins is already functionally expressed in
differentiating ESCs. Of note, in adult cardiac cells all of these
proteins are known targets of PKG-I activity [9], which thus
exert a fundamental regulatory function of intracellular Ca2+
homeostasis. In particular, PKG-I phosphorylates PLB and
enhances Ca2+ reuptake into SR by accelerating SERCA2a
activity [10, 11]; this mechanism increases SR Ca2+ content
that might accelerate the in/out Ca2+ cycling between SR
and cytosol. PKG-I also targets sodium/calcium exchanger
(NCX), which in turn contributes to its reverse mode to
cytosolic Ca2+ oscillations. Finally, sGC/PKG-I pathway is
reported to activate cytosolic Ca2+ influx via reverse mode
NCX activity [31]. In our setting, we hypothesize that the
growing functional expression of PKG-I during differentia-
tion, throughmodulation of cytosolicCa2+ cycling,may favor
the induction of Ca2+ discharge from SR and the progression
of the cardiogenic process.
In conclusion, our research supports the idea that PKG-
I pathway is a key promoter to drive ES cell differentiation
in cardiac cell. Though further research is necessary, these
findings suggest that treatments able to increase PKG-I activ-
ity in vivo (i.e., NO/CO-donors, direct activator of sGC, and
PDE5 inhibitors) could be effective in stimulating resident
cardiac stem cells to differentiate in mature cardiac cells,
favoring cardiac healing and ameliorating the ischemic insult.
A thorough preclinical assessment of survival, proliferation,
and cardiac differentiation of stem cells will clarify the
plausibility of this hypothesis and will shed novel light into
the benefits of NO-donors in cardiac ischemia and other
degenerative pathologies.
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